GlassScriptPhysician profile
Gene T Robichaux
NPI 1255793634
$1,195.67
in general payments reported to CMS, 2019-2025
13 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $19.95 · 2021: $63.78 · 2022: $113 · 2023: $189 · 2024: $181 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $471.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $333.52 | 2019-2023 | Ingrezza |
| Abbvie INC. | $143.15 | 2022-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $129.05 | 2019-2024 | Abilify Maintena |
| Lundbeck LLC | $111.17 | 2019-2023 | Rexulti |
| Tris Pharma INC | $100.53 | 2021-2025 | Dyanavel Xr |
| Alkermes, INC. | $91.40 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $90.73 | 2023-2024 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $51.38 | 2023-2025 | Spravato |
| Corium, LLC | $40.92 | 2022 | |
| Allergan, INC. | $38.54 | 2019 | |
| Axsome Therapeutics, INC. | $31.99 | 2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $19.50 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.79 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Robichaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.